{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:35Z","timestamp":1792801775271,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA296410"],"award-info":[{"award-number":["R01CA296410"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA062924"],"award-info":[{"award-number":["P50CA062924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA248624"],"award-info":[{"award-number":["K08CA248624"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74711-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:46:19Z","timestamp":1782211579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-7567","authenticated-orcid":false,"given":"Hejia Henry","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-8985","authenticated-orcid":false,"given":"Amanda L.","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Daniel","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-9183","authenticated-orcid":false,"given":"Christopher","family":"Thoburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatcher R.","family":"Heumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Bever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-9041","authenticated-orcid":false,"given":"Michael J.","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-7697","authenticated-orcid":false,"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Baretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-0748","authenticated-orcid":false,"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-0200","authenticated-orcid":false,"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Nauroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6549","authenticated-orcid":false,"given":"Elizabeth M.","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer S.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0049","authenticated-orcid":false,"given":"Neeha","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"74711_CR1","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andr\u00e9","year":"2024","unstructured":"Andr\u00e9, T. et al. Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer. N. Engl. J. Med. 391, 2014\u20132026 (2024).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini, M. et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat. Rev. Clin. Oncol. 22, 385\u2013407 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74711_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng, C. et al. Colorectal cancer. Lancet 404, 294\u2013310 (2024).","journal-title":"Lancet"},{"key":"74711_CR4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR5","doi-asserted-by":"publisher","unstructured":"Overman, M. J. et al. Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.3501 (2016)","DOI":"10.1200\/JCO.2016.34.15_suppl.3501"},{"key":"74711_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","volume":"6","author":"EX Chen","year":"2020","unstructured":"Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study. JAMA Oncol. 6, 831 (2020).","journal-title":"JAMA Oncol."},{"key":"74711_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2022.40.4_suppl.107","volume":"40","author":"GM Vaccaro","year":"2022","unstructured":"Vaccaro, G. M. et al. Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J. Clin. Oncol. 40, 107 (2022).","journal-title":"J. Clin. Oncol."},{"key":"74711_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med."},{"key":"74711_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"74711_CR10","doi-asserted-by":"publisher","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","volume":"4","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw. Open 4, e2118416 (2021).","journal-title":"JAMA Netw. Open"},{"key":"74711_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","volume":"9","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 9, 627 (2023).","journal-title":"JAMA Oncol."},{"key":"74711_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep29765","volume":"6","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki, M., Hemminki, A., Sundquist, J. & Hemminki, K. Patterns of metastasis in colon and rectal cancer. Sci. Rep. 6, 29765 (2016).","journal-title":"Sci. Rep."},{"key":"74711_CR13","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR14","doi-asserted-by":"publisher","unstructured":"Sahin, I. H., Ciombor, K. K., Diaz, L. A., Yu, J. & Kim, R. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. Am. Soc. Clin. Oncol. Educ. Book https:\/\/doi.org\/10.1200\/EDBK_349811 (2022).","DOI":"10.1200\/EDBK_349811"},{"key":"74711_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","volume":"2","author":"PMK Westcott","year":"2021","unstructured":"Westcott, P. M. K. et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat. Cancer 2, 1071\u20131085 (2021).","journal-title":"Nat. Cancer"},{"key":"74711_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi, N., Jaffee, E. M. & Yarchoan, M. Recent advances in therapeutic cancer vaccines. Nat. Re v. Cancer 25, 517\u2013533 (2025).","journal-title":"Nat. Re v. Cancer"},{"key":"74711_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"74711_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"74711_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"74711_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"74711_CR21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"74711_CR22","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 40, 1010\u20131026.e11 (2022).","journal-title":"Cancer Cell"},{"key":"74711_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"74711_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"74711_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"74711_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."},{"key":"74711_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"74711_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","volume":"52","author":"Z Hu","year":"2020","unstructured":"Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701\u2013708 (2020).","journal-title":"Nat. Genet."},{"key":"74711_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-024-07747-9","volume":"633","author":"AJ Cornish","year":"2024","unstructured":"Cornish, A. J. et al. The genomic landscape of 2,023 colorectal cancers. Nature 633, 127\u2013136 (2024).","journal-title":"Nature"},{"key":"74711_CR30","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1158\/1078-0432.CCR-23-1212","volume":"30","author":"GP Linette","year":"2024","unstructured":"Linette, G. P., Bear, A. S. & Carreno, B. M. Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin. Cancer Res. 30, 2017\u20132024 (2024).","journal-title":"Clin. Cancer Res."},{"key":"74711_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"74711_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68324-4","volume":"17","author":"AL Huff","year":"2026","unstructured":"Huff, A. L. et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat. Commun. 17, 1538 (2026).","journal-title":"Nat. Commun."},{"key":"74711_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"74711_CR35","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"74711_CR37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942\u2013948 (2022).","journal-title":"Nature"},{"key":"74711_CR38","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau, T. et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405, 1851\u20131864 (2025).","journal-title":"Lancet"},{"key":"74711_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"74711_CR40","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","volume":"27","author":"DP Modest","year":"2016","unstructured":"Modest, D. P. et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann. Oncol. 27, 1746\u20131753 (2016).","journal-title":"Ann. Oncol."},{"key":"74711_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"74711_CR42","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR43","doi-asserted-by":"publisher","first-page":"e2308511120","DOI":"10.1073\/pnas.2308511120","volume":"120","author":"R Sender","year":"2023","unstructured":"Sender, R. et al. The total mass, number, and distribution of immune cells in the human body. Proc. Natl. Acad. Sci. USA. 120, e2308511120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74711_CR44","doi-asserted-by":"publisher","first-page":"eabe3348","DOI":"10.1126\/sciadv.abe3348","volume":"7","author":"A Cachot","year":"2021","unstructured":"Cachot, A. et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci. Adv. 7, eabe3348 (2021).","journal-title":"Sci. Adv."},{"key":"74711_CR45","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse, B. et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618, 1033\u20131040 (2023).","journal-title":"Nature"},{"key":"74711_CR46","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 42, 1202\u20131216.e8 (2024).","journal-title":"Cancer Cell"},{"key":"74711_CR47","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery, F. J. et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat. Med. 31, 1994\u20132003 (2025).","journal-title":"Nat. Med."},{"key":"74711_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"74711_CR49","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 184, 596\u2013614.e14 (2021).","journal-title":"Cell"},{"key":"74711_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. 29, 440\u2013449 (2023).","journal-title":"Nat. Med."},{"key":"74711_CR51","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"74711_CR52","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1158\/1078-0432.CCR-21-0180","volume":"27","author":"JM Loree","year":"2021","unstructured":"Loree, J. M. et al. Clinical and functional characterization of atypical KRAS\/NRAS mutations in metastatic colorectal cancer. Clin. Cancer Res. 27, 4587\u20134598 (2021).","journal-title":"Clin. Cancer Res."},{"key":"74711_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR54","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR55","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"74711_CR56","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"74711_CR57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"74711_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"74711_CR59","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","volume":"15","author":"M Orlen","year":"2025","unstructured":"Orlen, M. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma. Cancer Discov. 15, 1697\u20131716 (2025).","journal-title":"Cancer Discov."},{"key":"74711_CR60","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2014.02.055","volume":"146","author":"BP Keenan","year":"2014","unstructured":"Keenan, B. P. et al. A listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146, 1784\u20131794.e6 (2014).","journal-title":"Gastroenterology"},{"key":"74711_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1593\/tlo.09268","volume":"2","author":"HX Barnhart","year":"2009","unstructured":"Barnhart, H. X. & Barboriak, D. P. Applications of the repeatability of quantitative imaging biomarkers: a review of statistical analysis of repeat data sets. Transl. Oncol. 2, 231\u2013235 (2009).","journal-title":"Transl. Oncol."},{"key":"74711_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74711-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:03:47Z","timestamp":1786014227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74711"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74711-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.H. is a consultant for Adventris Pharmaceuticals. S.D.H. reports research funding from Shionogi, Summit Therapeutics, Bristol Myers Squibb, and travel\/honoraria from DAVA Oncology. K.M.B. reports research support from BMS and Merck. Her spouse is an employee of AstraZeneca. D.T.L. is a consultant for Bristol Myers Squibb. E.S.C. reports grant\/research support from Affimed GMBH, Parabilis, Haystack, Incyte, NextCure, Pfizer, and Regeneron. E.S.C. is a consultant for Parabilis, Roche, Seres Therapeutics, SirTex, and Urogen. M.Y. receives grant\/research support (to Johns Hopkins) from Bristol-Myers Squibb, Exelixis, Incyte, and Genentech; receives honoraria from Exelixis, AstraZeneca, Lantheus, Genentech, and Incyte; M.Y. is the co-inventor of patents related to cancer vaccines (patents managed by Johns Hopkins); and is a cofounder with equity of Adventris Pharmaceuticals. E.M.J. reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, Surge Tx, Mestag, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. E.M.J. is a founder of, holds equity in, and serves as a consultant to Adventris Pharmaceuticals. Furthermore, Adventris Pharmaceuticals has licensed a technology described in this study from the Johns Hopkins University. As a result of that agreement, Dr. Jaffee and the University are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. N.S.A. is a paid consultant for Mirati and QED, receives institutional funding from Agios Inc, Array, Atlas, Bayer HealthCare, Bristol Myers Squibb, Celgene, Debio, Eli Lilly and Company, EMD Serono, Incyte Corporation, Intensity, Merck & Co., and Taiho Pharmaceuticals Co. Ltd. Dr. Azad participates on advisory boards for Incyte, QED, and GlaxoSmithKline. N.Z. reports research support from Bristol Myers Squibb, is a consultant for Genentech, and receives other support from Adventris Pharmaceuticals. A.H.L., M.Y., E.M.J., and N.Z. have currently filed patents related to the KRAS peptide vaccine. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7880"}}